-

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or the “Company”) (NASDAQ: TMDX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.

CLICK HERE TO LEARN MORE

TransMedics Group operates an organ transplant ecosystem under which it offers patented technology to preserve and mobilize organs, services that support transplant centers and medical teams, and a logistics arm that facilitates the entire chain. On October 28, 2024, the Company released its 3Q24 financial results. During the associated earnings call, the Company revealed that its revenue missed its estimates by a wide margin and that revenues were down sequentially. On this news, the Company’s stock price fell $39.24, or more than 30%, on October 29, 2024, on high trading volume.

What You Can Do – CLICK HERE FOR YOUR OPTIONS AS A SHAREHOLDER

If you purchased or otherwise own TransMedics Group securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Nicholas Bruno at (888) 398-9312 or at nbruno@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

This may be considered Attorney Advertising.

Contacts

Nicholas Bruno
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 24th Floor, New York, NY 10169
(888) 398-9312
nbruno@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:TMDX

Release Versions

Contacts

Nicholas Bruno
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 24th Floor, New York, NY 10169
(888) 398-9312
nbruno@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

UTZ BRANDS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Utz Brands, Inc.’s Directors and Officers for Breach of Fiduciary Duties – UTZ

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Utz Brands, Inc. (NYSE: UTZ) approved a buyout of Utz for inadequate consideration, breaching their fiduciary duties to Utz’s shareholders, and whether Utz’s shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On July 21, 2026, Utz announced it had reached an agreement t...

UTZ BRANDS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Utz Brands, Inc.’s Directors and Officers for Breach of Fiduciary Duties – UTZ

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Utz Brands, Inc. (NYSE: UTZ) approved a buyout of Utz for inadequate consideration, breaching their fiduciary duties to Utz’s shareholders, and whether Utz’s shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On July 21, 2026, Utz announced it had reached an agreement...

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation’s Directors and Officers for Breach of Fiduciary Duties – CHE

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Chemed Corporation (NYSE: CHE) failed to manage Chemed in an acceptable manner, breaching their fiduciary duties to Chemed, and whether Chemed and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On August 13, 2026, The Capital Forum released a report alleging t...
Back to Newsroom